Latest Facioscapulohumeral muscular dystrophy Stories

While not a household name, the FSH Society, dedicated to finding treatments for a crippling form of muscular dystrophy, has been lauded as “truly exceptional” by one of America’s premier charity evaluators. Lexington, MA (PRWEB) May 15, 2013 The Massachusetts-based FSH Society, Inc., has just been ranked among America’s “Ten Charities Worth Watching” by one of the nation’s leading charity watchdog organizations. According to Charity Navigator, “Many of America's most...

For the 15th year in a row, Chris Stenmon rallies his friends and family in the fight against facioscapulohumeral muscular dystrophy (FSHD). This year’s event will be held on April 27th at Florian Hall in Dorchester. Boston, MA (PRWEB) April 22, 2013 When Chris Stenmon made it onto the Boston College High School wrestling team, he was eager to prove his athletic prowess at the sports-loving school. Yet hard as he trained, he wasn’t getting stronger, and he eventually consulted an...

Conference to include data from Sarepta, GSK/Prosensa on exon-skipping trials for Duchenne dystrophy, plus updates on many other potential therapies TUCSON, Ariz., April 22, 2013 /PRNewswire-USNewswire/ -- Some 500 members of the scientific and medical research community are scheduled to attend the 2013 MDA Scientific Conference, "Therapy Development for Neuromuscular Diseases: Translating Hope into Promise," April 21-24 in Washington, D.C., according to representatives of the...

Dedicated to finding treatments for facioscapulohumeral muscular dystrophy (FSHD), the patient-driven FSH Society has been awarded Charity Navigator’s coveted four-star rating for the fifth year in a row. Lexington, MA (PRWEB) April 08, 2013 Hard on the heels of its most successful fundraising year ever, the Massachusetts-based FSH Society, Inc., has earned the highest-possible rating from one of the nation’s premier charity evaluators. For the fifth consecutive year, the FSH Society...

SARM Could Represent a New Category of Therapy for Duchenne Muscular Dystrophy, Potential for Other Neuromuscular Diseases CAMBRIDGE, Mass., March 20, 2013 /PRNewswire/ -- DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV. In early studies, the drug candidate, renamed DT-200, demonstrated...

TUCSON, Ariz., Feb. 14, 2013 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association, Parent Project Muscular Dystrophy and the Foundation to Eradicate Duchenne today called on the U.S. Senate and the U.S. House of Representatives to reauthorize the MD CARE Act of 2001, and to continue federal support for the accelerated pace of research and treatment development for muscular dystrophy. The nonprofits also are urging the public to contact their U.S. Senators and ask them to vote...

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy. The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy, or FSHD, by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the disease. The...

33 New Projects Will Advance Neuromuscular Disease Research TUCSON, Ariz., Aug. 21, 2012 /PRNewswire-USNewswire/ -- Greater understanding of the causes and natural histories of neuromuscular diseases, and translation of the latest research advances into potential treatments are the focus of new projects funded by the Muscular Dystrophy Association's latest round of grants. (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO) MDA awarded 33 grants totaling $10,684,481...

TUCSON, Ariz., and PLEASANTON, Calif., Aug. 2, 2012 /PRNewswire-USNewswire/ -- Safeway Inc. kicked off its annual fundraising campaign for the Muscular Dystrophy Association August 1 to support health care services for those living with neuromuscular diseases and global MDA research initiatives. (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO) (Logo: http://photos.prnewswire.com/prnh/20120730/DC49109LOGO) The nationwide campaign runs through September 3, giving...

TUCSON, Ariz., May 7, 2012 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association announced today that an MDA-supported research team in Italy and Japan has identified a promising new target at which to aim experimental therapies to treat facioscapulohumeral muscular dystrophy (FSHD). (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO) "This is an exciting new development in FSHD," said MDA Vice President of Research Sanjay Bidichandani. "We're possibly a step...